CD34+ stem cell therapy: Additional Phase II data

Additional data from a double-blind, U.S. Phase II trial in 167 patients with chronic, severe angina showed that low-dose injections of Baxter's autologous hematopoetic CD34+ stem cells injected into 10 locations into the heart led to significantly fewer episodes of angina per week at both 6 (6.8 vs. 10.9) and 12 months (6.3 vs. 11) vs. placebo. Additionally, patients who received low-dose injections of CD34+ stem cells were able to exercise on a treadmill for significantly longer at both 6 (139 vs. 69 seconds) and 12 months (140 vs. 58 seconds) vs. placebo. The study was conducted by Baxter and researchers at Northwestern University's Feinberg School of Medicine. Data were published in Circulation Research. ...